JP EN

INTRODUCTION

HIROSHI KAWAMOTO

Rebirthel Co., Ltd. was founded in October, 2019.
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal
T cells that are regenerated from pluripotent stem cells.
The strategy is based on methods developed by myself, Dr. Hiroshi Kawamoto (Kyoto University).

It has been shown to be effective to transfuse genetically engineered T cells that had originally been collected from patients.
However, such “autologous” settings have faced problems: costly, time-consuming, and dependent on the quality of the T cells themselves (from the patients).
To solve these problems, Rebirthel provides “off-the-shelf T cells” that can be universally used with any patients in an allogeneic setting.

Pluripotent stem cells such as iPS (induced pluripotent stem) cells or ES (embryonic stem) cells have the potential to produce various types of tissues/organs.
Rebirthel has already established a method by which potent killer T cells can be produced in vitro from iPS cells.
Using this method, Rebirthel is now developing a strategy where tumor antigen-specific T cells are mass-produced and transfused to patients as off-the-shelf T cells.

Certain types of T cells play the role of commander of immune cells, while other types serve as strong warriors.
Therefore, if we can produce different types of T cells - such as killer T cells, helper T cells, or regulatory T cells - covering a wide range of target antigens, we can provide therapeutic T cells targeting any kind of disease related to the immune system (e.g. cancer, infectious diseases, autoimmune diseases, allergies, etc.).

Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease.

COMPANY PROFILE

Message from the President

”We are pioneering a new era for treating diseases through the transfusion of T cell preparations!”
Rebirthel provides a novel treatment through a highly universal T cell preparation.

Rebirthel was founded in October 2019 with the aim of providing novel treatments against cancer, infectious diseases, and other immune-related diseases. Our strategy is based upon the technology of killer T cell regeneration from pluripotent stem cells, which was pioneered by Professor Hiroshi Kawamoto, Director of the Institute for Life and Medical Sciences, Kyoto University.

Cancer is still the leading cause of death in the world with over 20 million annual new cases (over one million diagnosed in Japan alone). Sixty percent of these cases are treatable via current protocols; however, the other forty percent are presently almost totally untreatable.

Tumor immunology has made remarkable progress. Immunotherapies such as immune checkpoint blockade or CAR-T cell therapy have shown high therapeutic efficacy on some cancers. Moreover, the mRNA vaccine developed for SARS-CoV-2 has shown remarkable success in protection against the novel coronavirus infection. Attention is increasingly focused on the natural immune system all human beings are born with, including immunotherapy and immune functions.

Rebirthel is one of the leading companies in the field of immunotherapy and has multiple globally patented technologies. These technologies enable us to produce a novel immunotherapy using killer T cells that are regenerated from pluripotent stem cells, which can be used to treat immune-related disorders such as cancer, infectious diseases, autoimmune diseases, and allergies.

In addition to our development pipeline, we also promote business and public-private-academic partnerships. We believe these collaborations contribute to the development of immune therapies throughout the entire industry, helping us to treat patients using T cell preparations as early as possible.

”We are pioneering a new era for treating diseases through the transfusion of T cell preparations!” Rebirthel makes every effort to further develop and realize novel immunotherapies.

I would like to express my sincere gratitude for your continued support and encouragement.

Rebirthel Co., Ltd.
President and CEO
Masunori Kajikawa

Name
Rebirthel Co., Ltd.
ADDRESS
Room 311, Creation Core Kyoto Mikuruma, 448-5,
Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
ESTABLISHED
Oct 1st, 2019
Capital stock
30,000,000 JPY
President
Masunori Kajikawa
Director
Toshio Kitamura
Aim
Development and operationalization of cell-based cancer immunotherapies

Business Summary

Rebirthel operationalizes cell-based cancer immunotherapies developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).
Rebirthel will provide “universal” cytotoxic T lymphocytes regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” in cancer immunotherapy.

Company history

January 2016
Regcell Co., Ltd. founded by Dr. Shimon Sakaguchi
April 2016
Hiroshi Kawamoto joined Regcell. Regcell aims to realize cell therapy using regulatory T cells or killer T cells.
May 2017
Regcell allocated new shares to third party and increased capital to 6,000,000 USD.
August 2017
Regcell allocated new shares to third party and increased capital to 200,000 USD.
October 2019
Rebirthel Co., Ltd. was founded by dividing Regcell into Regcell and Rebirthel.
Rebirthel took over all projects and intellectual properties related to killer T cells.
・Regcell raised 620,000,000 JPY through a third-party allocation of new shares.
・Regcell raised 20,000,000 JPY through a third-party allocation of new shares.

COMPANY INTRODUCTION

Rebirthel develop novel method for T cell therapy and provides “off-the-shelf T cells” against cancer.

(1) Killer T cells regenerated from HLA-matched iPS cells(1) Killer T cells regenerated from HLA-matched iPS cells

Transferred cells will immediately be rejected if the HLA haplotype does not match to that of the recipient.
In the regenerative medicine field, induced pluripotent stem (iPS) cells stock projects have been promoted where iPS cells that have been produced from healthy donors carrying the same HLA haplotype in both mother and father-derived alleles.
The cells/tissues regenerated from such iPS cells are expected to be transplanted to recipients who have the same HLA haplotype of at least one allele without inducing a severe rejection reaction.
At present, the most frequent four iPS cell lines are available from the Center for iPS Cell Research and Application (Kyoto University), covering 35% of the Japanese population.
We transduce these iPS cells with exogenous TCR and regenerate killer T cells from these iPSCs. Such regenerated T cells will be given to the patients in a HLA homo-to-hetero transfusion setting.

(2) Killer T cells regenerated from HLA-deleted iPS/ES cells(2) Killer T cells regenerated from HLA-deleted iPS/ES cells

When the HLA genes of iPS cells are deleted, cells/tissues regenerated from such HLA-null-iPS cells can be transplanted to any patient.
This strategy can be applied not only for iPS cells but also for ES cells.

PRODUCTION

OP9 cell line and its genetically modified derivatives

Rebirthel has succeeded all rights of the OP9 cells from Dr. Hiroaki Kodama (who originally established the OP9 cell line).
You are required to obtain a license from Rebirthel for commercial use of the OP9 cell line or its derivatives.

OP9 cells

NEWS

NEWS 2022.8.1 Rebirthel was selected for subsidy program “Forest of Industry-Academia-Government” by Public Interest Incorporated Foundation KYOTO Industrial Support Organization 21 for the second year in succession.

Public Interest Incorporated Foundation KYOTO Industrial Support Organization 21 has announced the names of companies receiving the subsidy for FY 2022. As was the case last year, Rebirthel was select...

NEWS 2022.7.5 Rebirthel won the JETRO award at the 7th HVC (Healthcare Venture Conference) KYOTO 2022.

HVC Kyoto, Japan’s largest English-spoken pitch event specializing in health care, was held on July 5th, 2022. This event was supported by Japan External Trade Organization (JETRO), Kyoto prefecture, ...

NEWS 2022.6.17 2022 BIO International Convention

Rebirthel participated in the exhibition “2022 BIO International Convention”, held at San Diego Convention Center, San Diego, the US, from June 13th to June 16th, 2022. Our booth was allocated in the ...

NEWS 2022.6.9 We will be exhibiting at the 2022 BIO International Convention

“2022 BIO International Convention (BIO2022)” will be held at San Diego Convention Center from June 13th to June 16th, 2022 and Rebirthel will run a booth in the area of Japan pavilion which Japan Ext...

NEWS 2022.3.28 Rebirthel is nominated as a finalist in three categories for Informa Pharma Intelligence Awards

Informa Pharma Intelligence is the Japanese version of Scrips Awards which is world famous with a history of over 17 years in England. This year, Informa Pharma Intelligence will be held for the first...

NEWS 2022.3.3 Rebirthel won the Kyoto University Award at 3rd Kyoto University LifeScience Showcase 2022 @ San Diego

Graduate School of Medicine, Kyoto University has its research center on the campus of University of California, San Diego. To encourage the operationalization of research seeds and technologies devel...

NEWS , Press release 2021.12.16 Rebirthel and Otsuka Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology

Rebirthel Co., Ltd. announces that it entered into an exclusive commercial licensing agreement with Otsuka Pharmaceutical Co., Ltd. for our technologies on CAR-T/TCR-T genetically engineered cell prod...

Media , NEWS 2021.10.22 Rebirthel was featured on Nihon Keizai Shimbun (Japanese newspaper)

In the morning edition of Nihon Keizai Shimbun on October 22nd, 2021 (Page 18, Technology), Rebirthel’s research and development activity was introduced. In the article entitled “iPS cell technology r...

NEWS 2021.10.15 Japan Healthcare Venture Summit 2021

Rebirthel participated in the exhibition “Japan Healthcare Venture Summit 2021 (JHVS2021)”, held at PACIFICO Yokohama from October 13th to October 15th, 2021. Our booth was allocated in JST (Japan Sci...

NEWS , メディア 2021.8.18 Rebirthel was introduced on the web magazine “Nikkei Biotechnology & Business”

“The dictionary of Biotech Startups in Japan 2021-2022” which covers over 400 bio venture companies was published in June 2021. The news site “Nikkei Biotechnology & Business” is posting a serial ...

See the list of NEWS

CONTACT






    Privacy Policy

    We will not use your personal information for any purpose other than contacting customers.
    Please be sure to read our privacy policy.